https://www.selleckchem.com/pr....oducts/aminooxyaceti
Meanwhile, the systolic blood pressure was increased and diastolic blood pressure and arterial elastance were decreased after PF-04449613 treatment (P less then 0.05). (2) PF-04449613 (0.001, 0.01, 0.1, 1 μmol/L) significantly increased the left ventricular developed pressure (LVDP) in a concentration-dependent manner in vitro (P less then 0.05). (3) PF-04449613 (5 μmol/L) significantly increased the amplitude of SR Ca2+ transients mediated by facilitating sarcoplasmic reticulum Ca2+-ATPase-2a (SERCA2a) (P
Like
Comment
Share
